絞り込み

16644

広告

医学博士のブドウで造る北海道ワイン 異例の人気で増産態勢 (毎日新聞)

雪に覆われたぶどう畑を背景に、将来の夢を語る濱田さん=北海道三笠市達布で2019年12月13日、渡部宏人撮影 [PR] 旧産炭地の北海道三笠市で新規就農したがん...

  1. [医学] イルベサルタンがマルファン症候...
  2. [医学] TET発現低下に伴う皮膚幹細胞...
  3. 超高均一で究極に透明 常識を覆すゲルを東...
  4. [医学] 細菌性膣炎とIL-36γ発現亢...

ニュース一覧

「elotuzumab」の検索結果

248件中 1件~20件表示    検索結果をPubMedで見る PubMedで見る

Monoclonal Antibody Therapies in Multiple Myeloma: A Challenge to Develop Novel Targets.

Optimal sequence of daratumumab and elotuzumab in relapsed and refractory multiple myeloma.

Elotuzumab plus lenalidomide and dexamethasone for newly diagnosed multiple myeloma: a randomized, open-label, phase 2 study in Japan.

Elotuzumab in combination with pomalidomide and dexamethasone for the treatment of multiple myeloma.

A Novel Approach to Remove Interference of Therapeutic Monoclonal Antibody with Serum Protein Electrophoresis.

[Management of multiple myeloma in the relapsed/refractory patient].

Activity of TAS4464, a novel NEDD8 activating enzyme E1 inhibitor, against multiple myeloma via inactivation of NF-κB pathways.

Advanced systemic mastocytosis with strong expression of signaling lymphocyte activation marker family member 7 (SLAMF7) responsive to therapy with elotuzumab and lenalidomide.

Monoclonal Antibody: A New Treatment Strategy against Multiple Myeloma.

Treatment of relapsed multiple myeloma: Evidence-based recommendations.

Enhanced SLAMF7 homotypic interactions by elotuzumab improves NK cell killing of multiple myeloma.

Monoclonal antibody utilization characteristics in patients with multiple myeloma.

Multiple Myeloma Vaccination Patterns in a Large Health System: A Pilot Study.

Update on elotuzumab for the treatment of relapsed/refractory multiple myeloma: patients' selection and perspective.

Soluble SLAMF7 promotes the growth of myeloma cells via homophilic interaction with surface SLAMF7.

Increased SLAMF7 monocytes in myelofibrosis patients harboring JAK2V617F provide a therapeutic target of elotuzumab.

Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma.

Immunotherapy in Multiple Myeloma: Accelerating on the Path to the Patient.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
Sort by
※並べ替えは表示に時間がかかります